Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert(Johns Hopkins University SAIS Bologna Center), Minesh P. Mehta(Columbia University), Kurt A. Jaeckle(Jacksonville College), Walter J. Curran(Piedmont Cancer Institute), Kristen I. Hopkins(The University of Texas MD Anderson Cancer Center), Deborah T. Blumenthal, Terri S. Armstrong(The University of Texas MD Anderson Cancer Center), Anita Mahajan(The University of Texas MD Anderson Cancer Center), Monika E. Hegi(University Hospital of Lausanne), Roger Stupp(Northwestern University), Sara Erridge(The University of Texas MD Anderson Cancer Center), Minhee Won(American College of Radiology), Kenneth Aldape(National Institutes of Health), Paul D. Brown(Mayo Clinic), Brigitta G. Baumert(Kantonsspital Graubünden), Tzahala Tzuk-Shina(The University of Texas MD Anderson Cancer Center), Meihua Wang(Nantong University), Jeffrey S. Wefel(The University of Texas MD Anderson Cancer Center), Arnab Chakravarti(The Ohio State University), Christopher J. Schultz(Medical College of Wisconsin)
Cited by 1,074
Related Papers
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2004|3.2k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k